Quanta Dialysis Technologies Ltd, an Alcester, England, and Beverly, MA-based medical technology company focusing dialysis care, raised $245m in Series D funding.
The round was led by Glenview Capital and co-led by Novo Holdings, with participation from BlackRock, Eldridge, Sands Capital, Millennium Management, Monashee Investment Management LLC., Puhua Capital, Segulah Medical and Ancora, alongside Orlando Health, an integrated delivery network, and existing shareholders Wellington Partners, btov, Seroba Life Sciences and The Grands. In conjunction with the funding, Lee Hathaway, Partner and Co-Head of Healthcare at Glenview Capital, and Robert Ghenchev, Senior Partner at Novo Holdings and Head of Novo Growth, will be joining the Quanta Board of Directors.
The company intends to use the funds to scale up global operations with a focus on the United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and chronic care facilities, invest in infrastructure to scale up manufacturing, sales and customer service functions to support use in currently approved care settings within the United States, while also preparing to launch a study to support its future FDA clearance for in-home use within the United States.
Led by John E. Milad, CEO, Quanta has developed a portable hemodialysis system SC+, which is an hemodialysis system designed to provide flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been used to treat patients across a range of care settings, from the ICU and the clinic to the home.
The patented technology behind SC+ is based on a design innovation that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The digitally connected design of SC+ is intended to empower patients to take control of their lives with selfcare and home dialysis.